SCYNEXIS, Inc. (NASDAQ:SCYX) Q2 2022 Results Conference Call August 15, 2022 8:30 AM ET

Company Participants

Debbie Etchison - Communications and IR

Dr. Marco Taglietti - President and CEO

Christine Coyne - Chief Commercial Officer

Dr. David Angulo - Chief Medical Officer

Larry Hoffman - Interim CFO

Conference Call Participants

Carvey Leung - Cantor Fitzgerald

Farhana Sakloth - Ladenburg Thalmann

Oren Livnat - H.C. Wainwright

Kumar Raja - Brookline Capital Markets

Steve Brozak - WBB Securities

Operator

Ladies and gentlemen, good morning, and welcome to SCYNEXIS, Inc. Second Quarter 2022 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I will now turn the conference over to Ms. Debbie Etchison, Communications and Investor Relations. Please go ahead.

Debbie Etchison

Thank you. Hello, everyone, and welcome to today’s conference call to discuss our second quarter 2022 financial results and corporate update.

Before we start, let me remind you that today’s call will include forward-looking statements based on current expectations, including statements concerning our financial outlook for the future, leadership’s expectations for our future financial and operational performance, as well as our business strategy. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

Please refer to our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and quarterly report on Form 10-Q, including in each case under the caption Risk Factors, in another document subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements speak only as of today, August 15, 2022. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. The information on today’s call is not intended for promotional purposes and not sufficient for prescribing decisions.

Joining us today’s call are SCYNEXIS President and CEO, Dr. Marco Taglietti; Chief Commercial Officer, Christine Coyne; Chief Medical Officer, Dr. David Angulo; and Interim Chief Financial Officer, Larry Hoffman. Following our prepared remarks, we’ll open the call to your questions.

Now, I will turn the call over to Dr. Marco Taglietti, President and CEO.

Dr. Marco Taglietti

Thank you, Debbie. Good morning, everyone. Thank you for joining us today for our second quarter of 2022 earnings investor call.